U.S. Markets closed

Tempus Announces Collaboration with Abramson Cancer Center at Penn to Increase the Effectiveness of Immunotherapy Treatment

CHICAGO, Nov. 30, 2016 /PRNewswire/ -- Tempus, a technology company focused on supporting physicians delivering customized cancer care, and Penn's Abramson Cancer Center have partnered to better determine which patients will have a positive response to immunotherapy treatment based on next generation genomic and transcriptomic sequencing.

As part of a research collaboration, Tempus will provide sequencing and analysis of de-identified pancreatic and melanoma cancer patient data to Penn. Utilizing next-generation sequencing, machine learning and bioinformatics, Tempus will help physicians analyze these data sets for relevant patterns that can help inform which immunotherapies are most likely to be effective in a given cohort of patients.  

"Tempus is committed to bringing relevant information and technology to healthcare providers battling cancer," said Eric Lefkofsky, Co-founder and CEO of Tempus. "We are proud to partner with the Abramson Cancer Center and provide our expertise to the researchers and physicians who are doing innovative and groundbreaking work on the front lines of immunotherapy."

"We are thrilled to collaborate with Tempus, a company that shares our commitment to research and innovation toward the advancement of patient care," said Dr. Chi Van Dang, Professor & Director, Abramson Cancer Center. "Putting cutting-edge technology into the hands of our physicians enhances the resources they need to best serve their patients."

"At The University of Pennsylvania's Abramson Cancer Center, we believe that the cure for cancer is not only within reach, it's also within each of us," said Dr. Robert H. Vonderheide, Hanna Wise Professor in Cancer Research at the Perelman School of Medicine at the University of Pennsylvania and Associate Director for Translational Research at the Abramson Cancer Center.   "We are excited to partner with Tempus, who will bring their sequencing and analytic capabilities to our renowned team of researchers working tirelessly to advance our understanding of tumor immunology."

About Tempus: 
Tempus is a technology company that has built an operating system to battle cancer. Tempus enables physicians to deliver personalized cancer care through its interactive analytical and machine learning platform. The company provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data.

Tempus has recruited a world-class team of accomplished geneticists, computational biologists, data scientists and software engineers who have developed the software and analytic tools that form the foundation of an operating system to battle cancer. The company provides sequencing and analysis for top academic centers, hospital systems, associations, and health care providers.

For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com. 



Logo - http://photos.prnewswire.com/prnh/20160928/413117LOGO

Photo - http://photos.prnewswire.com/prnh/20161003/414721


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tempus-announces-collaboration-with-abramson-cancer-center-at-penn-to-increase-the-effectiveness-of-immunotherapy-treatment-300370091.html